TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02577432

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl
Description: Give 25 micro grams fentanyl intrathecal with one syringe. Then immediately give 10 mg hyperbaric bupivacaine intrathecally with an other syringe.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl
Description: Mix 25 micro grams fentanyl with 10 mg hyperbaric bupivacaine in one syringe. Give them intrathecally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric bupivacaine
Description: Give 25 micro grams fentanyl intrathecal with one syringe. Then immediately give 10 mg hyperbaric bupivacaine intrathecally with an other syringe.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hyperbaric bupivacaine
Description: Mix 25 micro grams fentanyl with 10 mg hyperbaric bupivacaine in one syringe. Give them intrathecally.
Study: NCT03449238

Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab
Description: Pembrolizumab infusion will be given on Day 4 (+/-1) after SRS treatment at the standard dose of 200mg IV over 30 minutes and repeated every 3 weeks until disease progression or unacceptable toxicity.
Study: NCT02449577

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beverage sequence ACDB
Description: Participants receive test beverages in the randomised order ACDB
Study: NCT04083144

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Repetitive Transcranial Magnetic Stimulation (Active)
Description: Active deep rTMS (10 Hz) using the H-coil to target the bilateral insula

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Deep Repetitive Transcranial Magnetic Stimulation (Sham)
Description: Sham deep rTMS using the H-coil. The sham coil is built into the same helmet as the active coil. It mimics the active coil with regards to acoustics and scalp sensations.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: 12 week course treatment of varenicline (0.5 mg/1 mg) using the standard dosage schedule for smoking cessation (Day 1-3: 0.5 mg daily; day 4-7: 0.5 mg twice a day; day 8-end of treatment: 1 mg twice a day).

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Varenicline
Description: 12 week course treatment of varenicline (0.5 mg/1 mg) using the standard dosage schedule for smoking cessation (Day 1-3: 0.5 mg daily; day 4-7: 0.5 mg twice a day; day 8-end of treatment: 1 mg twice a day).
Study: NCT02894983

Intervention type: OTHER
Group type: OTHER
Intervention: Flexion-ulnar cast
Description: The group will be treated with closed reduction and flexion-ulnar deviation position cast. This will take place under local anaesthesia by means of local infiltration commonly used in Finland. There is no preferable method for performing the reduction. Additional radiographs will be taken to verify the success of the reduction one week after the reduction and after two and five weeks of casting if treating health care professional it requires. The cast will be disposed after 5 weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: Functional cast
Description: The group will be treated with closed reduction and functional position cast. This will take place under local anaesthesia by means of local infiltration commonly used in Finland. There is no preferable method for performing the reduction. Additional radiographs will be taken to verify the success of the reduction one week after the reduction and after two and five weeks of casting if treating health care professional it requires. The cast will be disposed after 5 weeks.
Study: NCT02948595

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video feedback followed by structured verbal feedback
Description: Video feedback followed by structured verbal feedback

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured verbal feedback followed by video feedback
Description: Structured verbal feedback followed by video feedback
Study: NCT01260415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab, Oxaliplatin, 5-FU
Description: * Panitumumab 6 mg / kg, given over 60 minutes~* Oxaliplatin 85 mg / m2 combined with leucovorin 400 mg / m2, given over 2 hours OR~* Irinotecan 180 mg / m2 , given over 90 minutes, concurrent with leucovorin 400 mg / m2, given over 90 minutes~* 5FU 400 mg / m2, by bolus infusion~* 5FU 2400 mg / m2, given over 46 hours
Study: NCT02504385

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Timocco
Description: Timocco virtual reality system is a motion based comuter games that was designed for child development therpay. The children will play Timocco for 15 minutes every session.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional OT intervention
Description: Traditional Occupational Therapy intervention will be givven to the control group.
Study: NCT01334112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib (AG-013736)
Description: 5mg, oral, twice daily, continuous dosing. A dosing cycle is defined as 4 weeks. Treatment may continue until disease progression/relapse
Study: NCT00828386

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Induction chemotherapy + concurrent radiochemotherapy vs. concurrent radiochemotherapy
Description: Induction chemotherapy (Docetaxel, Cisplatin and 5-Fluorouracil) + concurrent radiochemotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy + concurrent radiochemotherapy vs. concurrent radiochemotherapy
Description: Induction chemotherapy (Docetaxel, Cisplatin and 5-Fluorouracil) + concurrent radiochemotherapy
Study: NCT04194593

Intervention type: OTHER
Intervention: PCR (Polymerase Chain Reaction)
Description: Biological testing of FFPE (Formalin-Fixed Paraffin-Embedded) or frozen samples of tumors will be led. These tissues have been collected during the treatment of patients (for diagnostic purposes).~A molecular analysis (polymerase chain reaction) is led on DNA extracted from FFPE/frozen conserved tissues, and a result is produced by the algorithm.
Study: NCT01948934

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Amniotic membrane in big wounds
Description: The wound will be washed with saline and debrided if necessary. Control microbiological cultures will be taken and applied amniotic membrane fragments sufficient to cover the wound, putting in contact the basement membrane of the AM with granulation tissue
Study: NCT05024786

Intervention type: OTHER
Intervention: continuous quality improvements
Description: We implement the continuous quality improvement strategy in CQI group, and observe the effect of the strategy on the mortality of patients supported with ECMO .
Study: NCT01399086

Intervention type: DRUG
Intervention: Fulvestrant
Description: 250mg on d1,15,29 or 250mg on d1 q28days
Study: NCT04090749

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver-Support
Description: intervention incorporating 5 individualized, nurse-led, home-based sessions, with telephone check-ins and text reminders, according to participant preference. Caregiver-Support will help caregivers articulate statements of purpose in life, set goals to address fatigue and caregiver burden, provide instrumental support through a benefits check up and promote identification and increased connection with the caregiver's social network.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver-Support
Description: intervention incorporating 5 individualized, nurse-led, home-based sessions, with telephone check-ins and text reminders, according to participant preference. Caregiver-Support will help caregivers articulate statements of purpose in life, set goals to address fatigue and caregiver burden, provide instrumental support through a benefits check up and promote identification and increased connection with the caregiver's social network.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Caregiver-Support
Description: intervention incorporating 5 individualized, nurse-led, home-based sessions, with telephone check-ins and text reminders, according to participant preference. Caregiver-Support will help caregivers articulate statements of purpose in life, set goals to address fatigue and caregiver burden, provide instrumental support through a benefits check up and promote identification and increased connection with the caregiver's social network.
Study: NCT02528305

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity Interval Training
Description: 2 minute warm-up at 50rpm, then increase to 100rpm. Weight added to bike (7% body weight for men 6% body weight for women). Continue effort for 6 seconds, then passive rest for at least 1 minute. Total 5 sprints in sessions 1-3, 6 sprints in session4, 7 sprints in sessions 5\&6, 8 sprints in sessions 7\&8, 9 sprints in sessions 9\&10 and 10 sprints in sessions 11\&12.
Study: NCT00672204

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic islets of Langerhans transplant
Description: Up to 3 intraportal infusions of cadaveric pancreatic islets of Langerhans. Each infusion to contain at least 5,000 islet equivalents/kg body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raptiva
Description: Treatment Day -1 pretransplant to Treatment Day 90 after tx.: 1.0 mg/kg/wk SQ; Treatment Day 91 to Treatment Day 365: 0.5 mg/kg/wk SQ;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Initial dose 0.1 mg/kg PO on day -2, followed by 0.05 mg/kg daily, whole blood 24-hour trough adjusted to target 3-15 ng/ml as tolerated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: 2.0 mg/kg on days -2, and -1 IV
Study: NCT03325751

Intervention type: DIAGNOSTIC_TEST
Intervention: Visual field testing
Description: Standard Automated Perimetry using a perimeter is one of the most commonly used techniques for measuring perceived visual ability of a subject. For a given eye, it provides quantitative measurements of visual function represented as a 2D spatial visual field map. It is of great clinical importance for diagnosing and monitoring glaucoma and detecting neurological conditions.

Intervention type: DIAGNOSTIC_TEST
Intervention: Visual field testing
Description: Standard Automated Perimetry using a perimeter is one of the most commonly used techniques for measuring perceived visual ability of a subject. For a given eye, it provides quantitative measurements of visual function represented as a 2D spatial visual field map. It is of great clinical importance for diagnosing and monitoring glaucoma and detecting neurological conditions.
Study: NCT02854475

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Venous blood collection
Description: weekly within two weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Raman spectroscopy
Description: weekly within two weeks, on the volar forearm, using a RiverDiagnostics gen2-SCA Skin Composition Analyzer
Study: NCT01503112

Intervention type: OTHER
Intervention: No intervention, observational study
Study: NCT02652767

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GS010
Description: Both eyes of each participant will receive standard antiseptic preparation, administration of topical local ocular anesthetic agents and will undergo pupillary dilation. Administration of an intra-ocular pressure lowering agent will precede treatment for every participant.~GS010-treated Eyes: GS010 is a recombinant adeno-associated viral vector serotype 2 (rAAV2/2) containing the wild-type ND4 gene (rAAV2/2-ND4). Participants will receive a single dose of GS010 in one of their randomly selected eyes, via intravitreal injection containing 9E10 viral genomes in 90μL balanced salt solution (BSS) plus 0.001% Pluronic F68®.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Intravitreal Injection
Description: Both eyes of each participant will receive standard antiseptic preparation, administration of topical local ocular anesthetic agents and will undergo pupillary dilation. Administration of an intra-ocular pressure lowering agent will precede treatment for every participant.~Sham-treated Eyes: One eye of each participant will undergo sham injection. Sham intravitreal injection will be performed by applying pressure to the eye at the location of a typical intravitreal injection procedure using the blunt end of a syringe without a needle.
Study: NCT02620371

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: modified pectoral block
Description: Modified Pecs block was performed under general anesthesia, and 15 min. before skin incision. We performed the modified Pecs block or the  Pecs II block by using a two needle approach instead of one. The first puncture is a Pecs I block with 10 ml of local anesthetic injected between the two pectoralis muscles, and the second puncture injects 20 ml of local anesthetic between the Pectoralis minor muscle and the serratus muscle. This breaks through the 'axillary door' and will reach the long thoracic nerve and reliably at least two intercostal nerves.~We used A high frequency linear US probe is used for this block. a broadband linear array probe, with an imaging depth of 3-4cm. starting from the lateral third of the clavicle and moving distally and laterally to the mid axillary line.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: modified pectoral block
Description: Modified Pecs block was performed under general anesthesia, and 15 min. before skin incision. We performed the modified Pecs block or the  Pecs II block by using a two needle approach instead of one. The first puncture is a Pecs I block with 10 ml of local anesthetic injected between the two pectoralis muscles, and the second puncture injects 20 ml of local anesthetic between the Pectoralis minor muscle and the serratus muscle. This breaks through the 'axillary door' and will reach the long thoracic nerve and reliably at least two intercostal nerves.~We used A high frequency linear US probe is used for this block. a broadband linear array probe, with an imaging depth of 3-4cm. starting from the lateral third of the clavicle and moving distally and laterally to the mid axillary line.
Study: NCT05034666

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Before the education program
Description: Before applying the education program of the endotracheal cuff pressure inflation to the participating anaesthetists.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: After the education program
Description: After applying the education program of the endotracheal cuff pressure inflation to the participating anaesthetists.
Study: NCT01729247

Intervention type: DEVICE
Intervention: NIOX MINO® Instrument (09-1100)
Study: NCT03380936

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus Extended Release Oral Tablet [Envarsus]
Description: Switching from current version of tacrolimus to the extended release, once a day version (Envarsus) and titrating dose to achieve an optimal trough level. Goal trough tac level \> 8 ng/ml, MPA at 720 mg bid unless medically contraindicated, prednisone at current dose (5mg) or continue taper to 5mg per center standard of care protocol.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plasma Exchange and IVIG (Intravenous Immunoglobulin )
Description: Plasma exchange x 5 treatments, each followed by IVIG 200 mg/kg except last dose of 1 gm/kg. Rituximab 375 mg/m2 following final plasma exchange treatment.
Study: NCT03858439

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary
Description: Low sodium, low protein dietary recommendation
Study: NCT02398227

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HOPE
Description: Cognitive Behavioral Treatment for PTSD in Battered Women

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PCT
Description: Present Centered Therapy for PTSD
Study: NCT02889276

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Resistance Training
Description: Supervised group-based Functional Resistance Training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unsupervised activity
Description: General activity to meet 150 minutes of moderate intensity activity per week
Study: NCT00618839

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: StrataGraft Skin Tissue
Description: StrataGraft™ skin tissue is provided as a suturable circular patch of stratified epithelial tissue composed of a living dermal matrix (containing dermal fibroblasts) overlaid with human epidermal cells (NIKS™ cells).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cadaver allograft
Description: The standard of care for temporary coverage of full thickness skin defects is coverage with cadaver allograft until the wound can be autografted.
Study: NCT00712556

Intervention type: RADIATION
Intervention: fluorine 18-fludeoxyglucose positron emission tomography
Description: fluorine 18-fludeoxyglucose is a radioactive isotope used in PET to detect cancer tumors
Study: NCT02456103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ataluren
Description: Ataluren will be provided as a vanilla-flavored powder to be mixed with water or milk.
Study: NCT02721186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDA with DHAp and SLD Primaquine
Study: NCT02792621

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acipimox
Description: Oral supplement containing Acipimox 250mgs as the active ingredient in blinded label tablet form.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The placebo supplement will contain only cellulose microcrystalline. This is an inert substance widely used in many pill and tablet formulations. It is an insoluble fibre and is not absorbed into the blood stream therefore is unlikely to cause toxicity when taken orally.
Study: NCT03148119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QRH-882260 Heptapeptide
Description: topical spray; fluorescently-labeled peptide composed of a 7-amino acid sequence \[Gln-Arg-His-Lys-Pro-Arg-Glu\] attached via a 5 amino acid linker \[Gly-Gly-Gly-Ser-Lys\] to a near-infrared fluorophore, Cy5. The complete peptide sequence is written as: Gln-Arg-His-Lys-Pro-Arg-Glu-Gly-Gly-Gly-Ser-Lys(Cy5)-NH2, and is abbreviated as: QRHKPRE-GGGSK-(Cy5)-NH2.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scanning Fiber Endoscope
Description: Endoscope used for providing the light via laser to image the area of interest in the colon after the QRH has been sprayed and rinsed.
Study: NCT01504061

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mederma N&I
Description: Topical gel applied three times a day for eight weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mederma Ultra Gel
Description: Topical gel applied once daily for eight weeks.
Study: NCT01714388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: 1mcg/kg iv dose, followed by 5 minutes ECG recording
Study: NCT03094221

Intervention type: DEVICE
Intervention: Rhythmia Mapping System
Description: Arrhythmia mapping will be performed using the Rhythmia mapping system, including its mapping catheter, either in the atria or ventricles depending on the clinical arrhythmia being treated. Detailed mapping will be performed to determine tissue voltage and arrhythmia mechanism/location according to standard clinical practice. This part of the study will take approximately 90-120 minutes. The catheter position and contact will be visualized with intra-cardiac echocardiography, which is also routinely used during these procedures, and to monitor for potential clinically related complications. Images will be recorded to establish criteria for mapping.
Study: NCT01760980

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference product (A) Aromasin (Exemestane)
Description: Aromasin tablets will be administered under fasting conditions on two occasions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test product (B) Exemestane
Description: Exemestane tablets will be administered under fasting conditions on one occasion
Study: NCT02080000

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimisation of V-V timing using R wave on surface ECG

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard V-V timing settings
Study: NCT02472951

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low carbohydrate meals
Description: Meal macronutritional energy composition:~Carbohydrate 30% Protein 30% Fat 40%

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low carbohydrate meals
Description: Meal macronutritional energy composition:~Carbohydrate 30% Protein 30% Fat 40%

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low carbohydrate meals
Description: Meal macronutritional energy composition:~Carbohydrate 30% Protein 30% Fat 40%

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard carbohydrate meals
Description: Meal macronutritional energy composition:~Carbohydrate 55% Protein 15% Fat 30%

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard carbohydrate meals
Description: Meal macronutritional energy composition:~Carbohydrate 55% Protein 15% Fat 30%

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard carbohydrate meals
Description: Meal macronutritional energy composition:~Carbohydrate 55% Protein 15% Fat 30%
Study: NCT04179162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guérin (BCG)
Description: Patients will receive once-weekly intravesical BCG therapy (TICE strain, 50 mg) at weeks 2 (+/- 2 days), 3 (+/- 2 days), 5 (+/- 2 days), 6(+/- 2 days), 8 (+/- 2 days), and 9 (+/- 2 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Patients will receive gemcitabine at their specified dose level, given in a twice weekly fashion, with 72 to 96 h (+/- 1 day) between doses, at weeks 1, 4, 7, and 10.
Study: NCT04712227

Intervention type: OTHER
Intervention: intubation
Description: intubation
Study: NCT01597193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzalutamide
Description: 80 mg (2 capsules) or 160 mg (4 capsules) taken orally daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole
Description: 1 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane
Description: The exemestane dose is 25mg daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant
Description: 500 mg every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzalutamide
Description: 160 mg (4 capsules) taken orally daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzalutamide
Description: 160 mg (4 capsules) taken orally daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzalutamide
Description: 160 mg (4 capsules) taken orally daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzalutamide
Description: 160 mg (4 capsules) taken orally daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane
Description: The exemestane dose is 50 mg daily.
Study: NCT03472287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diacerein 1% Ointment
Description: Diacerein 1% Ointment administered topically

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diacerein 1% Ointment
Description: Diacerein 1% Ointment administered topically